UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

JNCI : Journal of the National Cancer Institute, 2018-06, Vol.110 (6), p.677-681

2018

Volltextzugriff (PDF)

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

International journal of cancer, 2013-10, Vol.133 (7), p.1653-1663

2013

Volltextzugriff (PDF)

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

The Journal of clinical investigation, 2009-05, Vol.119 (5), p.1251-1263

2009

Volltextzugriff (PDF)

Direct RIG‐I activation in human NK cells induces TRAIL‐dependent cytotoxicity toward autologous melanoma cells

International journal of cancer, 2019-04, Vol.144 (7), p.1645-1656

2019

Volltextzugriff (PDF)

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Oncoimmunology, 2018-02, Vol.7 (2), p.e1392426-e1392426

2018

Volltextzugriff (PDF)

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment

Oncoimmunology, 2018-01, Vol.7 (8), p.e1450127-e1450127

2018

Volltextzugriff (PDF)

Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D

Oncoimmunology, 2012-07, Vol.1 (4), p.535-536

2012

Volltextzugriff (PDF)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells

Oncoimmunology, 2013-08, Vol.2 (8), p.e25218-e25218

2013

Volltextzugriff (PDF)

Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events

International journal of cancer, 2003-03, Vol.103 (6), p.759-767

2003

Volltextzugriff (PDF)

Deciphering the genetic evolution of T-cell resistance in melanoma

Oncoimmunology, 2015-05, Vol.4 (5), p.e1005510-e1005510

2015

Volltextzugriff (PDF)

Database for queries of melanoma cohorts with molecular and clinical data

Pigment cell and melanoma research, 2023-03, Vol.36 (2), p.252-258

2023

Volltextzugriff (PDF)

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy

The Journal of clinical investigation, 2020-08, Vol.130 (8), p.4266-4281

2020

Volltextzugriff (PDF)

Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors

International journal of cancer, 2022-11, Vol.151 (9), p.1542-1554

2022

Volltextzugriff (PDF)

ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope

European journal of immunology, 2020-02, Vol.50 (2), p.270-283

2020

Volltextzugriff (PDF)

The proteasome immunosubunits, PA28 and ER‐aminopeptidase 1 protect melanoma cells from efficient MART‐126‐35‐specific T‐cell recognition

European journal of immunology, 2015-12, Vol.45 (12), p.3257-3268

2015

Volltextzugriff (PDF)

Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells

International journal of cancer, 2009-04, Vol.124 (7), p.1594-1604

2009

Volltextzugriff (PDF)

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy

The Journal of clinical investigation, 2020-08, Vol.130 (8), p.4266-4281

2020

Volltextzugriff (PDF)

New developments in biomarkers for melanoma

Current opinion in oncology, 2013-03, Vol.25 (2), p.145-151

2013

Volltextzugriff (PDF)

The proteasome immunosubunits, PA28 and ER‐aminopeptidase 1 protect melanoma cells from efficient MART‐1 26‐35 ‐specific T‐cell recognition

European journal of immunology, 2015-12, Vol.45 (12), p.3257-3268

2015

Volltextzugriff (PDF)

Interferon-y down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells

International journal of cancer, 2009, Vol.124 (7), p.1594-1604

2009

Volltextzugriff (PDF)

Rhodobacter capsulatus nifA mutants mediating nif gene expression in the presence of ammonium

FEMS microbiology letters, 2001-06, Vol.200 (2), p.207-213

2001

Volltextzugriff (PDF)

Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma

Experimental dermatology, 2003-12, Vol.12 (6), p.799-810

2003

Volltextzugriff (PDF)

Melanoma patients respond to a new HLA‐A01‐presented antigenic ligand derived from a multi‐epitope region of melanoma antigen TRP‐2

International journal of cancer, 2005-10, Vol.116 (6), p.944-948

2005

Volltextzugriff (PDF)

Identification of a new HLA‐A0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen

International journal of cancer, 2000-08, Vol.87 (3), p.399-404

2000

Volltextzugriff (PDF)

MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma

Cancer gene therapy, 2004-06, Vol.11 (6), p.408-418

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

KollektionWK Lippincott Williams & Wilkins–Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

Direct RIG‐I activation in human NK cells induces TRAIL‐dependent cytotoxicity toward autologous melanoma cells

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment

Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells

Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events

Deciphering the genetic evolution of T-cell resistance in melanoma

Database for queries of melanoma cohorts with molecular and clinical data

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy

Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors

ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope

The proteasome immunosubunits, PA28 and ER‐aminopeptidase 1 protect melanoma cells from efficient MART‐126‐35‐specific T‐cell recognition

Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy

New developments in biomarkers for melanoma

The proteasome immunosubunits, PA28 and ER‐aminopeptidase 1 protect melanoma cells from efficient MART‐1 26‐35 ‐specific T‐cell recognition

Interferon-y down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells

Rhodobacter capsulatus nifA mutants mediating nif gene expression in the presence of ammonium

Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma

Melanoma patients respond to a new HLA‐A01‐presented antigenic ligand derived from a multi‐epitope region of melanoma antigen TRP‐2

Identification of a new HLA‐A0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen

MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma

Aktive Filter

Suchergebnisse filtern